Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES EDWARD WILD

Allopathic & Osteopathic Physicians Family Medicine

NPI
1437140985
CMS profile
246081
Location
GOWANDA, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,192.63

64 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,192.63 64

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES EDWARD WILD

NPI 1437140985 · CMS profile ID 246081

Allopathic & Osteopathic Physicians / Family Medicine

GOWANDA, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437140985?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES EDWARD WILD, NPI 1437140985, CMS profile ID 246081. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437140985?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAMES EDWARD WILD, NPI 1437140985, CMS profile ID 246081. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437140985?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAMES EDWARD WILD, NPI 1437140985, CMS profile ID 246081, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1437140985?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

64 matching records · $1,192.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 64 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–64 of 64.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $22.3703/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997149807 CMS
Lilly USA, LLC $21.7903/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031484055 CMS
Lilly USA, LLC $14.9603/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031599893 CMS
PFIZER INC. $22.6603/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050618101 CMS
Novo Nordisk Inc $24.0802/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001527915 CMS
AstraZeneca Pharmaceuticals LP $13.3302/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014224817 CMS
Kowa Pharmaceuticals America, Inc. $24.1002/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003866675 CMS
Lilly USA, LLC $13.7702/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031541141 CMS
GlaxoSmithKline, LLC. $13.1602/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002309531 CMS
Novo Nordisk Inc $14.0502/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001527885 CMS
Lilly USA, LLC $16.8501/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031541155 CMS
Novo Nordisk Inc $13.0901/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001527873 CMS
AstraZeneca Pharmaceuticals LP $17.0801/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015807493 CMS
AbbVie Inc. $15.8001/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999628449 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,641.18 88
PY2020 $3,494.85 73
PY2021 $4,825.41 94
PY2022 $1,282.31 80
PY2023 $1,192.63 64
PY2024 $1,122.68 58
PY2025 $845.07 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $343,507.23 81
PY2024 Principal investigator $827,968.36 57
PY2023 Recipient $48,496.90 9
PY2023 Principal investigator $118,471.17 43
PY2022 Principal investigator $99,874.64 22
PY2021 Principal investigator $265,447.47 23
PY2020 Principal investigator $133,515.17 15
PY2019 Principal investigator $403,317.81 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOCIATES
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534941
Principal investigator 1 ABBVIE INC. $811.92 12/31/2025 Non-covered Recipient Entity
TEXAS MOVEMENT DISORDER SPECIALISTS
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor No dispute reported 06/30/2026 1202534943
Principal investigator 1 Acella Pharmaceuticals, LLC $8,051.69 12/18/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766885
Principal investigator 1 Ipsen Innovation $684.10 12/01/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296557
Principal investigator 1 Acella Pharmaceuticals, LLC $4,233.56 11/20/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766821
Principal investigator 1 GlaxoSmithKline, LLC. $125.00 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192154593
Principal investigator 1 GlaxoSmithKline, LLC. $85.80 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158430
Principal investigator 1 GlaxoSmithKline, LLC. $349.80 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158433
Principal investigator 1 GlaxoSmithKline, LLC. $139.92 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158438
Principal investigator 1 GlaxoSmithKline, LLC. $139.92 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158442
Principal investigator 1 GlaxoSmithKline, LLC. $1,019.32 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158446
Principal investigator 1 GlaxoSmithKline, LLC. $649.44 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158451
Principal investigator 1 GlaxoSmithKline, LLC. $190.08 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158454
Principal investigator 1 GlaxoSmithKline, LLC. $1,275.00 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158459
Principal investigator 1 GlaxoSmithKline, LLC. $279.84 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192158463
Principal investigator 1 GlaxoSmithKline, LLC. $85.80 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161450
Principal investigator 1 GlaxoSmithKline, LLC. $137.28 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161454
Principal investigator 1 GlaxoSmithKline, LLC. $205.92 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161463
Principal investigator 1 GlaxoSmithKline, LLC. $85.80 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161467
Principal investigator 1 GlaxoSmithKline, LLC. $279.84 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161472
Principal investigator 1 GlaxoSmithKline, LLC. $63.36 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161477
Principal investigator 1 GlaxoSmithKline, LLC. $68.64 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161481
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161486
Principal investigator 1 GlaxoSmithKline, LLC. $126.72 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161856
Principal investigator 1 GlaxoSmithKline, LLC. $209.88 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161864
Principal investigator 1 GlaxoSmithKline, LLC. $73.92 11/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192161870
Principal investigator 1 ABBVIE INC. $2,169.60 11/05/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202521347
Principal investigator 1 PFIZER INC. $7,488.70 10/23/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228720023
Principal investigator 1 Ipsen Innovation $2,965.62 10/22/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296545
Principal investigator 1 Ipsen Innovation $2,091.91 10/22/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296547
Principal investigator 1 Ipsen Innovation $2,965.62 10/22/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296549
Principal investigator 1 Ipsen Innovation $1,924.41 10/22/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296551
Principal investigator 1 Ipsen Innovation $2,965.62 10/22/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296553
Principal investigator 1 Ipsen Innovation $684.10 10/22/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296555
Principal investigator 1 ABBVIE INC. $5,000.00 10/16/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202517307
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 10/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOCIATES LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647572
Principal investigator 1 Merz Pharmaceuticals, LLC $8,500.00 10/10/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOCIATES LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647576
Principal investigator 1 PFIZER INC. $4,000.00 10/09/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228730988
Principal investigator 1 Merz Pharmaceuticals, LLC $8,500.00 10/08/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOCIATES LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647570
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 10/08/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOCIATES LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647574
Principal investigator 1 Acella Pharmaceuticals, LLC $2,778.24 10/03/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766894
Principal investigator 1 Acella Pharmaceuticals, LLC $4,630.40 10/03/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766905
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $22,176.02 09/24/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067937
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,986.70 09/24/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067939
Principal investigator 1 GlaxoSmithKline, LLC. $3,714.49 09/15/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192161459
Principal investigator 1 ABBVIE INC. $13,635.00 09/04/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202508872
Principal investigator 1 Acella Pharmaceuticals, LLC $1,250.00 08/28/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766587
Principal investigator 1 Acella Pharmaceuticals, LLC $2,112.00 08/28/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766632
Principal investigator 1 Acella Pharmaceuticals, LLC $926.08 08/22/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766549
Principal investigator 1 Acella Pharmaceuticals, LLC $1,389.12 08/22/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766628
Principal investigator 1 Acella Pharmaceuticals, LLC $1,852.16 08/22/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766794
Principal investigator 1 Ipsen Innovation $126.00 08/20/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296539
Principal investigator 1 ABBVIE INC. $3,732.10 08/06/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202502400
Principal investigator 1 Ipsen Innovation $1,240.00 08/02/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296541
Principal investigator 1 Ipsen Innovation $845.00 08/02/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296543
Principal investigator 1 Ipsen Innovation $1,705.86 07/30/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296531
Principal investigator 1 Ipsen Innovation $2,432.65 07/30/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296533
Principal investigator 1 Ipsen Innovation $1,584.34 07/30/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296535
Principal investigator 1 Ipsen Innovation $684.10 07/30/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296537
Principal investigator 1 ABBVIE INC. $3,936.20 07/02/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202496141
Principal investigator 1 ABBVIE INC. $517.40 06/03/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202489183
Principal investigator 1 Acella Pharmaceuticals, LLC $8,229.84 05/30/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766407
Principal investigator 1 ABBVIE INC. $2,169.60 05/07/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202482465
Principal investigator 1 Acella Pharmaceuticals, LLC $84,488.49 05/01/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766417
Principal investigator 1 Ipsen Innovation $2,965.62 04/28/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296525
Principal investigator 1 Ipsen Innovation $3,030.68 04/28/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296527
Principal investigator 1 Ipsen Innovation $2,965.62 04/28/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296529
Principal investigator 1 ABBVIE INC. $3,574.89 04/17/2025 Non-covered Recipient Entity
ALICE CASTILONE DBA UPSTATE CLINICAL RESEARCH ASSOCIATES LLC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202477539
Principal investigator 1 ABBVIE INC. $4,239.20 04/03/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202471849
Principal investigator 1 Acella Pharmaceuticals, LLC $9,202.71 03/28/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766327
Principal investigator 1 Acella Pharmaceuticals, LLC $3,865.29 03/28/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766331
Principal investigator 1 Acella Pharmaceuticals, LLC $8,566.99 03/28/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766343
Principal investigator 1 Acella Pharmaceuticals, LLC $6,304.51 03/28/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766373
Principal investigator 1 ABBVIE INC. $6,746.60 03/07/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202460773
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,812.60 02/28/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067883
Principal investigator 1 GlaxoSmithKline, LLC. $2,910.60 02/24/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192161860
Principal investigator 1 ABBVIE INC. $10,445.00 02/06/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202447687
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $15,844.50 01/24/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066905
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $6,867.90 01/14/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066901
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $6,500.00 01/14/2025 Non-covered Recipient Entity
Upstate Clinical Research Associates Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066903
Principal investigator 1 ABBVIE INC. $2,169.60 01/02/2025 Non-covered Recipient Entity
UPSTATE CLINICAL RESEARCH ASSOC LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202434241